|
| Status |
Public on Sep 18, 2024 |
| Title |
OLFM4 is a direct target of the cGAS-STING pathway and acts as an extracellular inhibitor for the Hippo signaling in EBV-associated cancer |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Aug 07, 2023 |
| Last update date |
Sep 18, 2024 |
| Contact name |
Fuping Wen |
| E-mail(s) |
wenfuping@sibcb.ac.cn
|
| Phone |
13488852923
|
| Organization name |
Shanghai Tenth People's Hospital
|
| Street address |
Yanchang Middle Road
|
| City |
Shanghai |
| ZIP/Postal code |
200072 |
| Country |
China |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (12)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE240274 |
OLFM4 is a direct target of the cGAS-STING pathway and acts as an extracellular inhibitor for the Hippo signaling in EBV-associated cancer |
| GSE240275 |
OLFM4 is a direct target of the cGAS-STING pathway and acts as an extracellular inhibitor for the Hippo signaling in EBV-associated cancer |
|
| Relations |
| BioProject |
PRJNA1003078 |
Less...
More...